ESC 2026: pooled on-treatment lipid-lowering efficacy of obicetrapib across the phase 3 trials (Mathijs de Kleer)

Mathijs de Kleer, Project Manager R&D at NewAmsterdam Pharma, the company that develops obicetrapib, presents a pooled on-treatment analysis of the phase 3 trials BROOKLYN, BROADWAY and TANDEM at ESC 2026, restricted to participants with pharmacologically confirmed exposure to the drug. An industry presentation of the LDL-C and apoB efficacy data across the programme; the outcomes question stays with PREVAIL.